July 10, 2024 — The headline is compelling. “Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study.” It certainly confirms the bias of a lot of people in the field. But is it true? Did tirzepatide (Zepbound) really beat semaglutide (Wegovy) in a head-to-head comparative study for obesity? In a word, no. Uncontrolled, Observational, and Inequivalent Dosing The […]
July 30, 2022 — It’s hard to argue with something dubbed “the sunshine vitamin” – more specifically, vitamin D. It’s been generating headlines and controversy for years now. The vitamin D fan club described it like a panacea, good for preventing bone fractures (of course), but also ills ranging from infections to diabetes and cancer. Because of its association […]
May 8, 2021 — It’s 2021 and the medical world has mostly moved on from the archaic view of bariatric surgery as a treatment of last resort for obesity. For many patients, delaying bariatric surgery harms their health. The rest of the world is still struggling to catch up. But healthcare providers who care for people living with obesity […]
March 24, 2021 — If you had any doubt about prior reports that semaglutide is likely to be a “game changer” for obesity care, perhaps you should look at JAMA today. Just one month after another paper in JAMA, semaglutide is back in the journal. This time, it is a 68-week study that shows the value of maintaining therapy […]
February 9, 2021 — Can a taste for sweetness predict how well someone will do after bariatric surgery? A new study in AJCN suggests that this may be so. In fact, this prospective observational study found two predictors of weight loss in a cohort of 96 bariatric surgery patients. One was an intense taste for sweetness. The other was […]
